A multi-year distribution and sales agreement lifted a Canadian biotech stock Friday. Here’s some small stocks making big moves on Friday, October 11, 2019 (as of 4:00 pm EST):
StageZero Life Sciences, Ltd (TSX:SZLS), a Canadian biotech stock, continued to move higher Friday, up 14% to $0.12 following a 31% gain on Thursday, after announcing that its licensing partner, Oncore Pharma, has signed a multi-year agreement with BodyCheck NL for the distribution and sale of ColonSentry throughout the Netherlands, Belgium and Luxembourg.
As well, shares of MTY Food Group Inc. (TSX:MTY) slipped 9% to $57.75 as the franchisor and operator of quick-service and casual dining restaurants said its third-quarter revenue rose 44% to $163.1 million, yet same-store sales for the quarter increased by just 0.3% compared to the same period last year.
Sonoro Energy Ltd. (TSXV:SNV), meanwhile, reported that it expects to sign the Selat Panjang Production Sharing Contract with the Indonesian Ministry of Energy on October 14, 2019. Sonoro Energy stock moved up 33% to $0.16 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
StageZero Life Sciences, Ltd (TSX:SZLS), a Canadian biotech stock, continued to move higher Friday, up 14% to $0.12 following a 31% gain on Thursday, after announcing that its licensing partner, Oncore Pharma, has signed a multi-year agreement with BodyCheck NL for the distribution and sale of ColonSentry throughout the Netherlands, Belgium and Luxembourg.
